"The EU approval of SYD-101 is a recognition of the compelling safety and efficacy data generated from our landmark STAR study," said Patrick Johnson, Ph.D., President of Sydnexis.

Story Continues "I am thrilled about the progress to bring SYD-101 to market for the millions of pediatric patients impacted by this growing epidemic," said Professor Mark Bullimore, OD, Ph.D.

Exclusive-Licensing Partner Santen Will Commercialize SYD-101 Under the Brand Name Ryjuneain the European Union Sydnexis, Inc., (www.sydnexis.com) a pre-commercial stage biopharmaceutical company ...

Santen is Sydnexis' Licensing Partner to Commercialize SYD-101 within the EMEA Region upon issuance of a Marketing Authorization by the European Commission Sydnexis, Inc. (www.sydnexis.com), a pre ...